A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases
- Univ. of Toronto, ON (Canada)
- Icahn School of Medicine at Mount Sinai, New York, NY (United States)
Protein arginine methyltransferases (PRMTs) play a crucial role in a variety of biological processes. Overexpression of PRMTs has been implicated in various human diseases including cancer. Consequently, selective small-molecule inhibitors of PRMTs have been pursued by both academia and the pharmaceutical industry as chemical tools for testing biological and therapeutic hypotheses. PRMTs are divided into three categories: type I PRMTs which catalyze mono- and asymmetric dimethylation of arginine residues, type II PRMTs which catalyze mono- and symmetric dimethylation of arginine residues, and type III PRMT which catalyzes only monomethylation of arginine residues. Here, we report the discovery of a potent, selective, and cell-active inhibitor of human type I PRMTs, MS023, and characterization of this inhibitor in a battery of biochemical, biophysical, and cellular assays. MS023 displayed high potency for type I PRMTs including PRMT1, -3, -4, -6, and -8 but was completely inactive against type II and type III PRMTs, protein lysine methyltransferases and DNA methyltransferases. A crystal structure of PRMT6 in complex with MS023 revealed that MS023 binds the substrate binding site. MS023 potently decreased cellular levels of histone arginine asymmetric dimethylation. It also reduced global levels of arginine asymmetric dimethylation and concurrently increased levels of arginine monomethylation and symmetric dimethylation in cells. We also developed MS094, a close analog of MS023, which was inactive in biochemical and cellular assays, as a negative control for chemical biology studies. In conclusion, MS023 and MS094 are useful chemical tools for investigating the role of type I PRMTs in health and disease.
- Research Organization:
- Argonne National Laboratory (ANL), Argonne, IL (United States)
- Sponsoring Organization:
- U.S. National Inst. of Health; AbbVie, Bayer Pharma AG; Boehringer Ingelheim; Canada Foundation for Innovation; Eshelman Inst. for Innovation; Genome Canada; Innovative Medicines Initiative (EU/EFPIA); ULTRA-DD; Janssen, Merck & Co.; Novartis Pharma AG; Ontario Ministry of Economic Development and Innovation; Pfizer; São Paulo Research Foundation-FAPESP; Takeda; Wellcome Trust
- Grant/Contract Number:
- R01GM103893; 1097737; 115766
- OSTI ID:
- 1243125
- Journal Information:
- ACS Chemical Biology, Vol. 11, Issue 3; ISSN 1554-8929
- Publisher:
- American Chemical Society (ACS)Copyright Statement
- Country of Publication:
- United States
- Language:
- ENGLISH
Web of Science
Similar Records
Protein arginine methyltransferase 1 regulates herpes simplex virus replication through ICP27 RGG-box methylation
Computational Study of Symmetric Methylation on Histone Arginine Catalyzed by Protein Arginine Methyltransferase PRMT5 through QM/MM MD and Free Energy Simulations